Clinical pharmacology of polyestradiol phosphate
- 1 January 1988
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 13 (4) , 299-304
- https://doi.org/10.1002/pros.2990130405
Abstract
The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only considerably increased estrogen concentration in plasma but also maintain the same estrone/estradiol ratio as in normal men. Monthly injections of PEP produce persistent elevation of the plasma estradiol levels throughout the dose interval, and rising PEP doses produce proportionately increasing steady‐state plasma concentrations of estradiol. The steady‐state plasma concentrations of testosterone are reduced to 45, 25, and 15% of the pretreatment concentrations after treatment every fourth week with 80, 160, and 240 mg PEP, respectively.Keywords
This publication has 7 references indexed in Scilit:
- Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphateThe Prostate, 1987
- Plasma Concentrations of Estradiol and Testosterone in Single-Drug Polyestradiol Phosphate Therapy for Prostatic CancerEuropean Urology, 1987
- Optimal Testosterone Concentration for the Treatment of Prostatic CancerJournal of Urology, 1985
- Metabolism of estramustine phosphate (Estracyt ®) in patients with prostatic carcinomaEuropean Journal of Drug Metabolism and Pharmacokinetics, 1981
- SERUM SEX-HORMONE BINDING GLOBULIN AND TESTOSTERONE BINDING AFTER ESTRADIOL ADMINISTRATION, CASTRATION, AND THEIR COMBINATION IN MEN WITH PROSTATIC-CARCINOMA1979
- Treatment of Prostatic Carcinoma with Various Types of Estrogen DerivativesPublished by Elsevier ,1976
- High Molecular Weight Enzyme Inhibitors. III. Polyestradiol Phosphate, a Long-acting Estrogen.Acta Chemica Scandinavica, 1958